Femasys Inc. has announced the initiation of a post-market surveillance clinical study for its CE-marked FemBloc Permanent Birth Control device in Europe. The study is being conducted in accordance with the European Union Medical Device Regulation (EU MDR 2017/745) and has received approval from multiple Ethics Committees. The trial aims to monitor the safety and performance of FemBloc in real-world settings and complies with ISO 14155:2020 for Good Clinical Practice and applicable national regulations. FemBloc is a non-surgical, permanent birth control solution designed to provide an alternative to traditional surgical sterilization. The results of the study have not yet been presented.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Femasys Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9550052-en) on October 22, 2025, and is solely responsible for the information contained therein.